Weight Loss Drugs Face Olympic Ban
The World Anti-Doping Agency is considering a ban on weight loss "jabs" (injectable medications) ahead of the next Olympics, citing concerns about athletes using them for performance enhancement and possible health risks. This move signals a shift in how sports officials view the intersection of medical weight loss and fair play in competition.
- The class of drugs under scrutiny is GLP-1 receptor agonists, which includes brand names like Ozempic, Wegovy, and Mounjaro. These medications were originally developed for treating Type 2 diabetes. - For a substance to be officially banned, it must meet at least two of three WADA criteria: it enhances performance, poses a health risk to athletes, or violates the spirit of sport. - While not currently prohibited, WADA has placed these drugs on its Monitoring Program since 2024 to gather data on potential misuse by athletes. A decision on a ban could come in 2027, potentially affecting the Los Angeles 2028 Olympics. - A significant health concern for athletes is that these drugs can cause the loss of lean muscle mass in addition to fat, which could negatively impact power, endurance, and recovery. - The primary performance-enhancing concern is the potential for rapid weight loss, which improves an athlete's power-to-weight ratio, a key factor in endurance sports like cycling and running. - Experts have voiced concerns that the drugs' appetite suppression can lead to chronic under-fueling and Relative Energy Deficiency in Sport (RED-S), a condition that impairs many body functions. - If a ban is enacted, athletes with a legitimate medical diagnosis such as Type 2 diabetes could still potentially use the medication by applying for a Therapeutic Use Exemption (TUE).
